CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients

Inclusion Criteria - all study arms: * Written informed consent obtained from the subject before any trial-related procedures are performed * \>= 18 years and \<= 75 years of age at time of consent * Able to perform routine blood testing (standard care for transplant recipients) * Understands and can read English Inclusion criteria - high viral load arm: * Recipient of an organ transplant (lung, heart, liver, kidney, pancreas, intestine alone or in combination) and on immunosuppression * CMV DNAemia ≥ 50,000 IU/ml in the first 2 weeks of CMV antiviral treatment with CMV antiviral dose appropriately adjusted for renal function Inclusion criteria - CMV primary infection after liver transplantation arm: \- Liver transplant recipients who are CMV IgG negative and received a CMV IgG positive donor (CMV D+/R-) with a primary CMV infection, defined as detected CMV DNAemia, including detected but below the limit of quantitation Inclusion criteria - CMV primary infection after lung transplantation arm: \- Lung transplant recipients who are CMV D+/R- with a primary CMV infection after discontinuation of CMV antiviral prophylaxis, defined as detected CMV DNAemia, including detected but below the limit of quantitation Exclusion Criteria: * History of hypersensitivity to or a prior severe reaction associated with the administration of CytoGam or other human immunoglobulin preparation * Receipt of effective CMV antiviral treatment, appropriately adjusted for renal function, for gr…